Header Logo

Connection

OLIVE ECKSTEIN to Child

Back to Details
This is a "connection" page, showing publications OLIVE ECKSTEIN has written about Child.
OLIVE ECKSTEIN
Connection Strength
0.309
Child
  1. Histiocytic Disorders of Childhood. Pediatr Rev. 2022 Oct 01; 43(10):561-571.
    View in: PubMed
    Score: 0.049
  2. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2235-2245.
    View in: PubMed
    Score: 0.048
  3. Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition. Blood. 2019 04 11; 133(15):1691-1694.
    View in: PubMed
    Score: 0.038
  4. Rituximab therapy for patients with Langerhans cell histiocytosis-associated neurologic dysfunction. Pediatr Hematol Oncol. 2018 Oct - Nov; 35(7-8):427-433.
    View in: PubMed
    Score: 0.038
  5. Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study. Arthritis Rheumatol. 2025 Feb; 77(2):226-238.
    View in: PubMed
    Score: 0.014
  6. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024 05 14; 8(9):2248-2258.
    View in: PubMed
    Score: 0.014
  7. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May; 204(5):1888-1893.
    View in: PubMed
    Score: 0.014
  8. IFN-? signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS. Blood Adv. 2021 09 14; 5(17):3457-3467.
    View in: PubMed
    Score: 0.011
  9. Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders. J Allergy Clin Immunol. 2022 02; 149(2):758-766.
    View in: PubMed
    Score: 0.011
  10. Incorporation of thiotepa in a reduced intensity conditioning regimen may improve engraftment after transplant for HLH. Br J Haematol. 2020 03; 188(6):e84-e87.
    View in: PubMed
    Score: 0.010
  11. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019 11; 66(11):e27929.
    View in: PubMed
    Score: 0.010
  12. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018 11; 142(5):1665-1669.
    View in: PubMed
    Score: 0.009
  13. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018 07 05; 132(1):89-100.
    View in: PubMed
    Score: 0.009
  14. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer. 2018 06 15; 124(12):2607-2620.
    View in: PubMed
    Score: 0.009
  15. Activating MAPK1 (ERK2) mutation in an aggressive case of disseminated juvenile xanthogranuloma. Oncotarget. 2017 Jul 11; 8(28):46065-46070.
    View in: PubMed
    Score: 0.009
  16. Evaluation of maternal and perinatal characteristics on childhood lymphoma risk: A population-based case-control study. Pediatr Blood Cancer. 2017 05; 64(5).
    View in: PubMed
    Score: 0.008
  17. Hydroxyurea: a new old therapy for Langerhans cell histiocytosis. Blood. 2016 11 17; 128(20):2462-2465.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.